🇺🇸 FDA
Patent

US 10001485

Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor

granted A61KA61K31/166A61K31/506

Quick answer

US patent 10001485 (Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor) held by The Regents of the University of California expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/166, A61K31/506, A61K45/06